Study MPX111381: A Dose-ranging Study Evaluating the Efficacy, Safety and Tolerability of GSK1838262 (XP13512) in the Prophylactic Treatment of Migraine Headache.
Phase of Trial: Phase II
Latest Information Update: 19 Jul 2013
At a glance
- Drugs Gabapentin enacarbil (Primary)
- Indications Migraine
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 19 Nov 2010 Actual end date (Jun 2010) added as reported by ClinicalTrials.gov.
- 19 Nov 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 08 Jul 2010 Primary endpoint 'Days with headache' has not been met according to media release from XenoPort and GlaxoSmithKline.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History